-
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
•
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities. Expanding Collaborations in Pharmaceutical InnovationFrance’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially…
-
SciClone Pharmaceuticals Gets NMPA Approval for Phase III Study of First-in-Class SERD Orserdu
•
SciClone Pharmaceuticals Inc. (HKG: 6600), a Chinese pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to conduct a Phase III bridging study for its drug Orserdu (elacestrant), the world’s first selective estrogen receptor degrader (SERD) originally developed by Eisai. The Phase III study, which is randomized,…
-
GL Capital and SciClone Pharmaceuticals Agree to Privatization and Delisting
•
GL Capital and SciClone Pharmaceuticals Inc (HKG: 6600) have jointly announced an agreement to privatize the Chinese firm and delist it from the Hong Kong Stock Exchange. SciClone, an integrated biopharmaceutical company, is engaged in both product development and commercialization with a focus on oncology and severe infections. The company’s…
-
SciClone and Menarini File for Import License of Antibacterial Drug Vaborem in Macau
•
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that its Italy-based strategic partner Menarini has submitted an import drug pre-license filing for Vaborem (meropenem vaborbactam) in Macau. The company is seeking regulatory approval for the new antibacterial drug to treat complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and complicated complex urinary…
-
SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China
•
SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces with SPH Health Commerce Co., Ltd and Hi Dr to establish an Internet hospital. The tripartite partnership aims to leverage digital healthcare solutions, although no financial details of the agreement have been disclosed. SciClone, known…
-
SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer
•
SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted a pre-licensing application for the import of Orserdu (elacestrant) in Macau, seeking approval for its use in treating advanced or metastatic breast cancer. Elacestrant, a next-generation selective estrogen receptor degrader (SERD) developed by Eisai (TYO:…
-
SciClone Pharmaceuticals Secures Exclusive Rights to Menarini Group’s Orserdu in China
•
China’s SciClone Pharmaceuticals Inc., (HKG: 6600) has entered into a licensing and cooperation agreement with the Italy-headquartered Menarini Group. This agreement grants SciClone exclusive development and commercialization rights to Menarini’s Orserdu (elacestrant) in China. SciClone will be responsible for conducting clinical trials, regulatory filings, and marketing and distribution of Orserdu…
-
SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group
•
China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) and Italy-headquartered Menarini Group. While specific details of the partnership remain undisclosed, this alliance marks a significant step for all parties involved. Focus on Oncology and Infectious Diseases SciClone is dedicated…
-
SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study
•
SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it has received approval from the US FDA to conduct a clinical study for its drug thymalfasin as a booster for COVID-19 mRNA vaccines. This marks a significant step in exploring new ways to enhance the…
